Evidence map›Paper›PMID 22504812›Full record

ArticleApplied and environmental microbiology2012

In vitro functional and immunomodulatory properties of the Lactobacillus helveticus MIMLh5-Streptococcus salivarius ST3 association that are relevant to the development of a pharyngeal probiotic product.

Valentina Taverniti, Mario Minuzzo, Stefania Arioli, Ilkka Junttila, Sanna Hämäläinen, Hannu Turpeinen, Diego Mora, Matti Karp, Marko Pesu, Simone Guglielmetti

Open access · bronzeAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Probiotics in addition to antibiotics for the treatment of acute tonsillitis: a randomized, placebo-controlled study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Trial
  2. Article
  3. Microorganisms · 2025
    Review
  4. Article
  5. Article
  6. Frontiers in pharmacology · 2022
    Article
  7. Article
  8. Surface Layer ofApplied and environmental microbiology · 2019
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Otitis media among high-risk populations: can probiotics inhibit Streptococcus pneumoniae colonisation and the risk of disease?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013
    Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Valentina TavernitiDepartment of Food Science and Microbiology, Università degli Studi di Milano, Milan, Italy.
Mario Minuzzo
Stefania Arioli
Ilkka Junttila
Sanna Hämäläinen
Hannu Turpeinen
Diego Mora
Matti Karp
Marko Pesu
Simone Guglielmetti
University of Milan · ITTampere University · FIFimlab (Finland) · FIPirkanmaa Hospital District · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of proper bacterial strains as probiotics for the pharyngeal mucosa is a potential prophylactic strategy for upper respiratory tract infections. In this context, we characterized in vitro the functional and immunomodulatory properties of the strains Lactobacillus helveticus MIMLh5 and Streptococcus salivarius ST3 that were selected during previous investigations as promising pharyngeal probiotics. In this study, we demonstrated in vitro that strains MIMLh5 and ST3, alone and in combination, can efficiently adhere to pharyngeal epithelial cells, antagonize Streptococcus pyogenes, and modulate host innate immunity by inducing potentially protective effects. In particular, we found that the strains MIMLh5 and ST3 activate U937 human macrophages by significantly inducing the expression of the proinflammatory cytokine tumor necrosis factor alpha (TNF-α). Nonetheless, the induction of the anti-inflammatory interleukin-10 (IL-10) by MIMLh5 or ST3 was never lower than that of TNF-α, suggesting that these bacteria can potentially exert a regulatory rather than a proinflammatory effect. We also found that the strains MIMLh5 and ST3 induce cyclooxygenase 2 (COX-2) expression and demonstrated that toll-like receptor 2 (TLR-2) participates in the recognition of the strains MIMLh5 and ST3 by U937 cells. Finally, we observed that these microorganisms grow efficiently when cocultured in milk, suggesting that the preparation of a milk-based fermented product containing both MIMLh5 and ST3 can be a practical solution for the administration of these bacteria. In conclusion, we propose the combined use of L. helveticus MIMLh5 and S. salivarius ST3 for the preparation of novel products that display probiotic properties for the pharyngeal mucosa.

Indexed as

AntibiosisBacterial AdhesionCells, CulturedCyclooxygenase 2Epithelial CellsHumansImmunologic FactorsInterleukin-10Lactobacillus helveticusMacrophagesPharynxProbioticsStreptococcusToll-Like Receptor 2Tumor Necrosis Factor-alphaCyclooxygenase 2Immunologic FactorsInterleukin-10PTGS2 protein, humanTLR2 protein, humanToll-Like Receptor 2Tumor Necrosis Factor-alpha

Identifiers

PMID22504812
PMCPMC3370528
OpenAlexW2073845202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.